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Abstract
We describe and compare four different methods for estimating sample size and power, when the primary
outcome of the study is a Health Related Quality of Life (HRQoL) measure. These methods are: 1. assuming a
Normal distribution and comparing two means; 2. using a non-parametric method; 3. Whitehead's method based
on the proportional odds model; 4. the bootstrap. We illustrate the various methods, using data from the SF-36.
For simplicity this paper deals with studies designed to compare the effectiveness (or superiority) of a new
treatment compared to a standard treatment at a single point in time. The results show that if the HRQoL
outcome has a limited number of discrete values (< 7) and/or the expected proportion of cases at the boundaries
is high (scoring 0 or 100), then we would recommend using Whitehead's method (Method 3). Alternatively, if the
HRQoL outcome has a large number of distinct values and the proportion at the boundaries is low, then we would
recommend using Method 1. If a pilot or historical dataset is readily available (to estimate the shape of the
distribution) then bootstrap simulation (Method 4) based on this data will provide a more accurate and reliable
sample size estimate than conventional methods (Methods 1, 2, or 3). In the absence of a reliable pilot set,
bootstrapping is not appropriate and conventional methods of sample size estimation or simulation will need to
be used. Fortunately, with the increasing use of HRQoL outcomes in research, historical datasets are becoming
more readily available. Strictly speaking, our results and conclusions only apply to the SF-36 outcome measure.
Further empirical work is required to see whether these results hold true for other HRQoL outcomes. However,
the SF-36 has many features in common with other HRQoL outcomes: multi-dimensional, ordinal or discrete
response categories with upper and lower bounds, and skewed distributions, so therefore, we believe these
results and conclusions using the SF-36 will be appropriate for other HRQoL measures.
Introduction
Health Related Quality of Life (HRQoL) measures are
becoming more frequently used in clinical trials as pri-
mary endpoints. Investigators are now asking statisticians
for advice on how to plan (e.g. estimate sample size) and
analyse studies using HRQoL measures.
Sample size calculations are now mandatory for many
research protocols and are required to justify the size of
clinical trials in papers before they will be accepted by
journals [1]. Thus, when an investigator is designing a
study to compare the outcomes of an intervention, an
essential step is the calculation of sample sizes that will
allow a reasonable chance (power) of detecting a prede-
termined difference (effect size) in the outcome variable,
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critically dependent on the purpose of the study, the out-
come measure and how it is summarised, the proposed
effect size and the method of calculating the test statistic
[2]. For simplicity in this paper we will assume that we are
interested in comparing the effectiveness (or superiority)
of a new treatment compared to a standard treatment at a
single point in time.
HRQoL measures such as the Short Form (SF)-36, Not-
tingham Health Profile (NHP) and European Organisa-
tion for Research and Treatment of Cancer (EORTC)
QLQ-C30 are described in Fayers and Machin [3] and are
usually measured on an ordered categorical (ordinal)
scale. This means that responses to individual questions
are usually classified into a small number of response cat-
egories, which can be ordered, for example, poor, moder-
ate and good. In planning and analysis, the responses are
often analysed by assigning equally spaced numerical
scores to the ordinal categories (e.g. 0 = 'poor', 1 = 'mod-
erate' and 2 = 'good') and the scores across similar ques-
tions are then summed to generate a HRQoL
measurement. These 'summated scores' are usually treated
as if they were from a continuous distribution and were
Normally distributed. We will also assume that there
exists an underlying continuous latent variable that meas-
ures HRQoL (although not necessarily Normally distrib-
uted), and that the actual measured outcomes are ordered
categories that reflect contiguous intervals along this
continuum.
However, this ordinal scaling of HRQoL measures may
lead to several problems in determining sample size and
analysing the data [4,5]. The advantages in being able to
treat HRQoL scales as continuous and Normally distrib-
uted are simplicity in sample size estimation and statisti-
cal analysis. Therefore, it is important to examine such
simplifying assumptions for different instruments and
their scales. Since HRQoL outcome measures may not
meet the distributional requirements (usually that the
data have a Normal distribution) of parametric methods
of sample size estimation and analysis, conventional sta-
tistical advice would suggest that non-parametric meth-
ods be used to analyse HRQoL data [3].
The bootstrap is an important non-parametric method for
estimating sample size and analysing data (including
hypothesis testing, standard error and confidence interval
estimation) [6]. The bootstrap is a data based simulation
method for statistical inference, which involves repeatedly
drawing random samples from the original data, with
replacement. It seeks to mimic, in an appropriate manner,
the way the sample is collected from the population in the
bootstrap samples from the observed data. The 'with
replacement' means that any observation can be sampled
more than once. HRQoL outcome measures actually gen-
erate data with discrete, bounded and non-standard distri-
butions. So, in theory, computer intensive methods such
as the bootstrap that make no distributional assumptions
may therefore be more appropriate for estimating sample
size and analysing HRQoL data than conventional statis-
tical methods.
Conventional methods of sample size estimation for stud-
ies with HRQoL outcomes are extensively discussed in
Fayers and Machin [3]. However, they did not use the
bootstrap to estimate sample sizes for studies with
HRQoL outcomes. As a consequence of this omission, the
aim of this paper is to describe and compare four different
methods, including the bootstrap for estimating sample
size and power when the primary outcome is a HRQoL
measure.
To illustrate this, we use some HRQoL data from a ran-
domised controlled trial, the Community Postnatal Sup-
port Worker Study (CPSW), which aimed to compare the
difference in health status in a group of women who were
offered postnatal support (intervention) from a commu-
nity midwifery support worker compared with a control
group of women who were not offered support [7]. The
primary outcome (used to estimate sample size for this
study) was the general health dimension of the SF-36 at 6
weeks postnatally.
Methods
SF-36 Health Survey
The SF-36 is the most commonly used health status meas-
ure in the world today [8]. It originated in the USA [9], but
has been validated for use in the UK [10]. It contains 36
questions measuring health across eight different dimen-
sions – physical functioning (PF), role limitation because
of physical health (RP), social functioning (SF), vitality
(VT), bodily pain (BP), mental health (MH), role limita-
tion because of emotional problems (RE) and general
health (GH). Responses to each question within a dimen-
sion are combined to generate a score from 0 to 100,
where 100 indicates "good health". Thus, the SF-36 gener-
ates a profile of HRQoL outcomes, (see Figure 1), on eight
dimensions.
Which sample size formulae?
In principle, there are no major differences in planning a
study using HRQoL outcomes, such as the SF-36, to those
using conventional clinical outcomes. Pocock [11] out-
lines five key questions regarding sample size:
1. What is the main purpose of the trial?
2. What is the principal measure of patient outcome?Page 2 of 17
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difference?
4. What type of results does one anticipate with standard
treatment?
5. How small a treatment difference is it important to
detect and with what degree of certainty?
Given answers to all of the five questions above, we can
then calculate a sample size.
The choice of the sample size formulae strictly depends on
the way data will be analysed, which in turn depends on
specific characteristics of the data analysed. For this reason
this paper is not only a comparison of four methods of
sample size calculation, but also the comparison of the
power of four different methods of analysis. We describe
four methods of sample-size estimation when using the
SF-36 in the comparative clinical trials of two treatments
(Table 1). The first method (Method 1) assumes the vari-
ous individual dimensions of the SF-36 are continuous
and Normally distributed. The second method (Method
2) assumes the SF-36 dimensions are continuous. The
third method (Method 3) assumes the SF-36 is an ordered
categorical outcome. The fourth method uses a bootstrap
approach.
In this paper the bootstrap has two roles. It is one of the
four methods of sample size calculation and consequently
analysis but it is also the method used to estimate the
power curves presented in the figures. The bootstrap, in
the way used in this paper, is a procedure for evaluating
the performance of the statistical procedures, including
tests. The bootstrap is non parametric in the sense that it
evaluates the performance of any test statistic without
making assumptions about the form of the distribution.
For the methods of sample size estimation, we consider
three test statistics, Methods 1, 2 and 3 and evaluate two
of them in two ways, one using the usual assumptions
(Normality or continuity), and the other by generating
bootstrap distributions from the data.
Method 1 Normally distributed continuous data – 
comparing two means
Suppose we have two independent random samples x1,
x2,...,xm and y1, y2,....,yn, of HRQoL data of size m and n
respectively. The x's are y's are random samples from con-
tinuous HRQoL distributions having cumulative distribu-
tion functions (cdfs), Fx and Fy respectively. We will
consider situations where the distributions have the same
shape, but the locations may differ. Thus if δ denotes the
location difference (i.e. mean (y) - mean (x) = δ), then
FY(y) = FX(y - δ), for every y. We shall focus on the null
hypothesis H0: δ = 0 against the alternative HA: δ ≠ 0. We
can test these hypotheses using an appropriate signifi-
cance test (e.g. t-test). With a Normal distribution under
the location shift assumption and with n = m, the neces-
sary sample size to achieve a power of 1-β is given in Table
1.
Method 2 continuous data using non-parametric methods
If the HRQoL outcome data (i.e. the GH dimension of the
SF-36) is assumed continuous and plausibly not sampled
from a Normal distribution then the most popular (not
necessarily the most efficient), non-parametric test for
comparing two independent samples is the two-sample
Mann-Whitney U (also known as the Wilcoxon rank sum
test) [12].
Suppose (as before) we have two independent random
samples of x's and y's and we want to test the hypothesis
that the two samples have come from the same popula-
tion against the alternative that the Y observations tend to
be larger than the X observations. As a test statistic we can
use the Mann-Whitney (MW) statistic U, i.e., U = #(yj > xi),
i = 1,...,m; j = 1,...,n, which is a count of the number of
times the yjs are greater than the xis. The magnitude of U
has a meaning, because U/nm is an estimate of the prob-
ability that an observation drawn at random from popu-
lation Y would exceed an observation drawn at random
from population X, i.e. Pr(Y > X).
Noether [13] derived a sample size formula for the MW
test (see Table 1), using an effect size pNoether, (i.e. Pr(Y >
X)), that makes no assumptions about the distribution of
the data (except that it is continuous), and can be used
whenever the sampling distribution of the test statistic U
can be closely approximated by the Normal distribution,
an approximation that is usually quite good except for
very small n [14].
Hence to determine the sample size, we have to find the
'effect size' pNoether or the equivalent statistic Pr(Y > X).
There are several ways of estimating pNoether, under various
assumptions, one non-parametric possibility is pNoether =
U/nm. Unfortunately, this can only be estimated after we
have collected the data and calculated the U statistic or by
computer simulation (as we shall see later). If we assume
that X ~ N(µX, σ2X) and Y ~ N(µY, σ2Y) then a parametric
estimate of Pr(Y > X) using the sample estimates of the
mean and variance ( ) is given by [15]:
where Φ is the Normal cumulative distribution function.
ˆ , ˆ , ˆ ˆµ σ µ σX X Y Y2 2,
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tion 1 allows the calculation of two comparable 'effect
sizes' pNoether and ∆Normal thus enabling the two methods
of sample size estimation to be directly contrasted. If the
SF-36 is not Normally distributed then we cannot use
equation 1 to calculate comparable effect sizes and must
rely on the empirical estimates of pNoether = U/nm calcu-
lated post hoc from the data. Alternatively, under the loca-
tion shift assumption, we can use bootstrap methods to
estimate pNoether.
Method 3 – Ordinal data and Whitehead's Odds Ratio
Whitehead [16] has derived a method for estimating sam-
ple sizes for ordinal data and suggested the odds ratio
(OROrdinal), which is the odds of a subject being in a given
category or lower in one group compared with the odds in
the other group, as an effect size. To use Whitehead's for-
mulae the proportion of subjects in each scale category for
one of the groups must also be specified.
Suppose there are two groups T and C and the HRQoL
outcome measure of interest Y has k ordered categories yi
denoted by i = 1,2,...,k. Let πiT be the probability of a ran-
domly chosen subject being in category i in Group T and
γiT be the expected cumulative probability of being in cat-
egory i or less in Group T (i.e. γiT = Pr(Y ≤ yi)). For category
i, where i takes values from 1 to k-1, the ORi is given in
Table 1.
The assumption of proportional odds specifies that the
ORi will be the same for all categories from i = 1 to k-1. As
the derivation of the sample size formulae and analysis of
data is based on the Mann-Whitney U test, Whitehead's
method can be regarded as a 'non-parametric' approach,
although it still relies on the assumption of a constant OR
for the data. Whitehead's method also assumes a relatively
small log odds ratio and a large sample size, which will
often be the case in HRQoL studies where dramatic effects
are unlikely [4]. Table 1 gives the number of subjects per
group nOrdinal for a two-sided significance level α and
power 1-β.
Whitehead's [16] method for sample determination is
derived from the proportional odds model. The propor-
tional odds model is equivalent to the MW test when
there is only a 0/1 (or group) variable in the regression
[17]. The advantage of the proportional odds model, over
the MW test is that it allows the estimation of confidence
intervals for the treatment group effect and for the adjust-
ment of the HRQoL outcome for other covariates.
If the number of categories is large, it is difficult to postu-
late the proportion of subjects who would fall in a given
Table 1: Effect size and sample size formulae
Method 1 Method 2 Method 3
Assumptions Normally distributed 
continuous data
Non-normally distributed 
continuous data
Ordinal data, constant and relatively small odds ratio, 
large sample size
Summary 
Measure
Mean and mean difference Median Odds Ratio (OROrdinal)
Hypothesis 
test
Two-independent samples t-test Mann-Whitney U test Mann-Whitney U test or equivalent proportional odds 
model
Effect Size pNoether = Pr(Y >X)
Sample size 
formulae
∆Normal is the standardised effect size index, µT and µC are the expected group means of outcome variable under the null and alternative hypotheses 
and σ is the standard deviation of outcome variable (assumed the same under the null and alternative hypotheses). pNoether is an estimate of the 
probability that an observation drawn at random from population Y would exceed an observation drawn at random from population X. Let πiT be 
the probability of being in category i in Group T and γiT be the expected cumulative probability of being in category i or less in Group T (i.e. γiT = 
Pr(Y ≤ yi)).  is the combined mean (of the proportion of patients expected in groups T and C) for each category i. z1-α/2 and z1-β are the 
appropriate values from the standard Normal distribution for the 100 (1 - α/2) and 100 (1 - β) percentiles respectively. Number of subjects per 
group n for a two-sided significance level α and power 1 - β.
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increase in power (and hence saving in the number of
subjects recruited) to be gained by increasing the number
of categories beyond five. An even distribution of subjects
within categories leads to the greatest efficiency.
Shepstone [18] demonstrates how the three seemingly
different effect size measures ∆Normal, OROrdinal and
pNoether, which are all numerical expressions of treatment
efficacy can be combined into a common scale. If Y and X
are the values of an outcome (higher values more prefera-
ble) for randomly selected individuals from the Treatment
and Control groups respectively, then AYX = Pr(Y > X), i.e.
the probability that the Treatment patient has an outcome
preferable to that of the Control patient, is equivalent to
the effect size statistic pNoether. If we let AXY = Pr(X > Y), i.e.
the probability that a random individual from group 2
(Control) has a better outcome than a random individual
from group 1 (Treatment), then
λ = AYX - AXY = Pr(Y >X) - Pr(X >Y)  (2)
and
Shepstone [18] shows that for ordinal and continuous
outcomes AYX - AXY = λ and AYX / AXY = θ are equivalent to
the Absolute Risk Reduction (ARR) and OR for binary out-
comes. AXY and AYX, or their equivalent statistics Pr(X > Y)
and Pr(Y > X) can be calculated by either a parametric
approach for continuous outcomes (Equation 1) via a the-
oretical distribution (e.g. Normal) or a non-parametric
approach without any distributional assumptions via the
Mann-Whitney U statistic. (Since AXY and AYX can be esti-
mated by  and  where UXY and
UYX are the values of the Mann-Whitney U statistics).
If the outcomes are continuous and/or can be fully ranked
and there are no ties in the data then Pr(X = Y) = 0 and λ
= AYX - AXY = Pr(Y > X) - Pr(X > Y) and θ = AYX/AXY = Pr(Y >
X)/Pr(X > Y) can be estimated exactly. Conversely, if there
are a large number of ties in the data, i.e. xi = yi, (which is
likely for HRQoL outcomes, with their discrete response
categories) then Pr(X = Y) > 0. In this case any pairs for
which xi = yi, contribute 1/2 a unit to both UYX and UXY.
Hence the two A statistics AYX and AXY can only be esti-
mated approximately and thus the approximate estimates
of θ and λ in the case of ties will be denoted by θ' and λ'
respectively.
Method 4 – Computer simulation – the bootstrap
Methods 1 and 2 assume the HRQoL outcome is continu-
ous and the simple location shift model is appropriate.
Here this would imply that, on a certain scale, the differ-
ence in effect of the intervention compared to the control
is constant or, at least that the intervention shifts the dis-
tribution of the HRQoL scores under the control to the
right (or to the left if the intervention is harmful) but
keeping its shape. However, the boundedness of the SF-36
outcomes renders this location shift assumption ques-
tionable, especially if the proportion of cases the upper
limit is high. Therefore, we used bootstrap methods to
compare the power of the t-test and MW test with allow-
ance for ties for detecting a shift in location using three
dimensions of the SF-36 (GH, RP and V) as outcomes
[14,19,20]. These three dimensions illustrate the different
distributions of HRQoL outcomes that are likely to occur
in practice.
Suppose (as before) we have two independent random
samples of x's and y's from continuous distributions hav-
ing cdfs, Fx and Fy respectively. Again we will consider sit-
uations where the distributions have the same shape, but
the locations may differ; i.e. mean (y) - mean (x) = δ. If we
focus on the null hypothesis H0: δ = 0 against the alterna-
tive HA: δ ≠ 0, then we can test this hypothesis using an
appropriate significance test (i.e. t-test, Mann-Whitney or
proportional odds model). However, we did not evaluate
the proportional odds model as part of the bootstrap. This
was because the proportional odds model is equivalent to
the MW test when there is only a 0/1 variable in the regres-
sion, and the p-values from the MW test and the signifi-
cance of the regression coefficient for the group variable
are indentical [17].
The bootstrap strategy is to use pilot data to a provide a
non-parametric estimate  of F and to use a simulation
method for finding the power of the test associated with
any specified sample size n if the data follow the esti-
mated distribution functions under the null and alterna-
tive hypotheses. If we denote the distribution function
estimate by , under the alternative hypothesis δ, we can
estimate the approximate power,  (G, δ, α, n) by the fol-
lowing computer simulation procedure [14,19,20].
Algorithm 1
Power and sample size estimation using the bootstrap
1. Draw a random sample with replacement of size 2 n
from F. The first n observations in the sample form a sim-
ulated sample of x's, denoted by x1*,...,xn*, with estimated
cdf *. Then δ is added to each of the other n observa-
tions in the sample to form the simulated sample of y's,
θ = = >( )
>( ) ( )
A
A
Y X
X Y
YX
XY
Pr
Pr
. 3
A
U
nmXY
XY
= A
U
nmYX
YX
=
Fˆ
Gˆ
πˆ
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and x*'s have been generated from the same distribution
except that the distribution of the y*'s is shifted δ units to
the right.)
2. The test statistic, Mann-Whitney or t-test, is calculated
for the x*'s and y*'s, yielding t(x*, y*). If t(x*, y*) ≥ T1-α/
2, (where T1-α/2 is the critical value of the test statistic) a
success is recorded; otherwise a failure is recorded.
3. Steps 1 and 2 are repeated B times. The estimated power
of the test,  (G, δ α, n), is approximated by the propor-
tion of successes among the B repetitions. (In all cases dis-
cussed in this paper, B = 10,000).
The bootstrap procedure described in Algorithm 1
assumes a simple location shift model. For bounded
HRQoL outcomes the procedure is in principle the same
but more imagination is needed to specify the effect of the
new treatment in comparison with the control treatment.
Under the simple location shift model, individual
improvement of δ points in HRQoL is assumed: for
bounded HRQoL outcome scores we have to assume an
effect δ1 (x) such that x + δ (x) remains in the interval
determined by the lower and upper boundary of the
HRQoL outcome. (In the case of the SF-36 GH dimension
between 0 and 100). One function is to assume a constant
treatment effect whenever possible. We assumed a con-
stant additional treatment effect of 5 points, until a GH
score of 95: patients with a GH score of 95 or more were
truncated at 100.
The software Resampling Stats was used for implementing
Algorithm 1 [21]. The bootstrap computer simulation
procedure involved using SF-36 data from a general pop-
ulation survey based on 487 women aged 16–74 as the
pilot dataset (Figure 1) [10].
Results
Sample size estimation – Method 1
When planning the CPSW study we went through
Pocock's [11] five key questions regarding sample size.
What is the main purpose of the trial?
To assess whether additional postnatal support by trained
Community Postnatal Support Workers could have a pos-
itive effect on the mother's general health.
What is the principal measure of patient outcome?
The primary outcome was the SF-36 general health per-
ception (GH) dimension at six weeks postnatally.
How will the data be analysed to detect a treatment difference?
We believed that the mean difference in GH scores
between the two groups was an appropriate comparative
summary measure and that a two-independent samples t-
test would be used to analyse the data.
What type of results does one anticipate with standard treatment?
Unfortunately no information was available from previ-
ous studies of new mothers to calculate a sample size
based on the GH dimension of the SF-36. Therefore as the
CPSW study was only going to involve women of child-
bearing age we estimated the standard deviation of the
GH outcome from a previous survey of the Sheffield gen-
eral population using (n = 487) females aged 16 to 45
(Figure 1g). This gave us an estimated SD of 20 [10].
How small a treatment difference is it important to detect and with 
what degree of certainty?
Using the GH dimension of the SF-36, a five-point differ-
ence is the smallest score change achievable by an individ-
ual and considered as "clinically and socially relevant"
[22].
Using Method 1, assuming a standard deviation σ of 20
and that a location shift or mean difference (µET - µEC) of
5 or more points between the two groups is clinically and
practically relevant, gives a standardised effect size, ∆Nor-
mal, of 0.25. Using this standardised effect size with a two-
sided 5% significance level and 80% power gives the esti-
mated required number of subjects per group as 253.
Sample size estimation – Method 2
Suppose we believe the GH dimension to be continuous,
but not Normally distributed and are intending to com-
pare GH scores in the two groups with a Mann-Whitney U
test (with allowances for ties). Therefore, Noether's
method will be appropriate. As before if we assume a
mean difference of 5 and a standard deviation of 20 for
the GH dimension of the SF-36, then using equation 1
leads to an parametric estimate of the effect size pNoether =
Pr(Y > X) of 0.57 and consequently Pr(X > Y) of 0.43.
Substituting pNoether = 0.57 in the formula for Method 2
(in Table 1) with a two-sided 5% significance level and
80% power gives the estimated number of subjects per
group as 267.
Method 1 has given us a slightly smaller sample size esti-
mate than Method 2. The two methods can be regarded as
equivalent when the two populations are Normally dis-
tributed, with equal variances. In this case, the MW test
will require about 5% more observations than the two-
sample t-test to provide the same power against the same
alternative. For non-Normal populations, especially those
with long tails, the MW test may not require as many
observations as the two-sample t-test [23].
Gˆ
πˆPage 7 of 17
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from the observed effect size data (using the observed
sample means and standard deviations), leads to values
very similar to the non-parametric estimate. For example,
for the GH dimension in the CPSW data in Table 2, the
observed non-parametric estimate of Pr(Y > X) was 0.542
compared to a parametric estimate of 0.537.
Sample size estimation – Method 3
Assuming a mean difference of 5 (i.e. )
and a common standard deviation of 20 (i.e.
) for the GH dimension of the SF-36,
then equation (1) leads to a parametric estimate of the
effect size pNoether = Pr(Y > X) of 0.57. This in turn leads to
a parametric estimate of the ARR (from equation 2), λ' =
0.57 - 0.43 = 0.14 and an estimated (from 3) OR θ' = 0.57/
0.43 = 1.33.
If we assume OROrdinal = OR = 1.33 then the assumption
of proportional odds specifies that the OROrdinali will be
the same for all 34 categories of the GH dimension. If we
also assume the proportion of subjects in each category in
the control group is the same as in Figure 1g. Then under
the assumption of proportional odds OROrdinal = 1.33, the
anticipated cumulative proportions (γiT) for each category
of treatment T are given by:
After calculating the cumulative proportions (γiT), the
anticipated proportions falling into each treatment cate-
gory, πiT can be determined from the difference in succes-
sive γiT. Finally, the combined mean ( ) of the
proportions of treatments C and T for each category is
calculated.
Substituting OROrdinal = 1.33 and  = 0.0067 with a
two-sided 5% significance level and 80% power gives the
estimated number of subjects per group as 584. Given this
sample size, and with the distribution shown in Figure 1g
and an OR of 1.33, we can work out what the
corresponding mean values are. The estimated mean GH
score was 77.6 in the treatment group and 75.0 in the con-
trol group. This is an estimated mean difference of 2.6
points, which is smaller than the five-point mean differ-
ence used earlier.
It is difficult to translate a shift in means into the shift in
the probabilities on an ordinal scale, without several
assumptions. If we assume proportions in each category
in the control group as shown in Figure 1g and propor-
tional odds shift, then an OROrdinal of 1.63 is approxi-
mately equal to a mean shift of 5.0. This leads to  =
0.007 and a sample size estimate of 199 subjects per
group with two-sided 5% significance and 80% power.
Given this sample size then the corresponding estimated
mean GH scores are 74.8 and 79.8 in the control and
treatment groups respectively.
Table 2: CPSW Study [7] Observed Effect Sizes for Control vs. Intervention Groups
SF-36 Dimension Group n mean sd Mean Diff δ ∆Normal PNoether Parametric Pr(Y > X) Non-parametric
Physical Control 241 89.9 14.5 2.6 0.17 0.548 0.561
Function Intervention 254 87.3 15.8
Role Control 241 74.3 38.1 9.1 0.23 0.566 0.568
Physical Intervention 254 65.2 39.5
Bodily Control 241 75.6 23.7 4 0.17 0.547 0.552
Pain Intervention 254 71.6 23.8
General Control 241 77.7 17.7 2.4 0.13 0.537 0.542
Health Intervention 254 75.3 18.5
Vitality Control 241 51.1 20.7 1.3 0.06 0.517 0.514
Intervention 254 49.8 21.7
Social Control 241 81.6 22.7 4.7 0.20 0.556 0.561
Function Intervention 254 76.9 24.2
Role Control 241 77.9 36.4 1.1 0.03 0.509 0.515
Emotional Intervention 254 76.8 35.5
Mental Control 241 72.9 17.2 -0.2 -0.01 0.497 0.499
Health Intervention 254 73.1 16.7
Effect size ∆Normal = mean difference divided by the pooled standard deviation. Effect size pNoether Pr(YControl > XIntervention), based on U/nm, where U 
= MW test statistic (with allowance for ties). Parametric estimate of Pr (Y > X) based on equation 1.
δ µ µ= − =ˆ ˆX Y 5
ˆ ˆ ˆσ σ σ= = =X Y 20
γ γγ γiT
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Figure 1g shows the skewed distribution of the GH dimen-
sion and that the underlying assumption of Normality of
the distribution required for Method 1 may not be appro-
priate. Furthermore the, GH dimension is bounded by 0
and 100. Thus, if a new mother already has a GH score of
100 in the control group, then under the intervention no
extra improvement can be seen, at least not by the GH
dimension of the SF-36. Seven percent of women (35/
487) in the Sheffield data had a GH score of 100 and
14.2% (70/487) had a score of 95 or more.
Figure 2 shows the estimated power curves for Methods 1,
2 and 3 and the two bootstrap methods (t and MW tests)
at the 5% two-sided significance level for detecting a loca-
tion shift (mean difference) δ = 5 in the SF-36 GH dimen-
sion using the data from the general population as our
pilot sample, for sample sizes per group varying from 50
to 600. For these general population data a location shift
of δ = 5 is equivalent to a standardised effect size ∆Normal =
0.25 and pNoether = Pr(Y > X) = 0.57. The bootstrap meth-
ods taking into account the bounded and non-Normal
distribution of the data suggest a mean difference d of 4.5
and p = Pr(Y > X) = 0.58.
The GH dimension (Figure 1g) of the SF-36 has a large
number (> 30) of discrete values or categories, most of
which are occupied, and the proportion scoring 0 or 100
is low. Figure 2 suggests that the MW test is more powerful
than the t-test for the GH dimension based on the boot-
strap results for the bounded shift. The power curves
shown in Figure 2 do not diverge too greatly and thus, the
location shift hypothesis is a useful working model.
In contrast, Figure 3 shows the estimated power curves for
another dimension of the SF-36: RP, which can only take
one of five discrete values (as shown in Figure 1c), for
detecting a simple location shift (mean difference) δ = 5.
For these data a simple location shift of δ = 5 is equivalent
to a standardised effect size ∆Normal = 0.17 and pNoether =
Pr(Y > X) = 0.55. Since three-quarters of the pilot sample
scored 100, the bootstrap methods under the location
shift model, taking into account the bounded and non-
Normal distribution of the data suggest a mean difference
d of 1.2 and p = Pr(Y > X) = 0.51. The power curves shown
in Figure 3 diverge greatly and the simple location shift
hypothesis may not be appropriate for this outcome. Fig-
ure 3 clearly shows the value of the bootstrap in investi-
gating the impact of the bounded HRQoL distributions
on the power of the hypothesis test.
Finally, Figure 4 shows the estimated power curves for the
Vitality dimension of the SF-36. This computer simulation
suggests that if the distribution of the HRQoL dimension
are reasonably symmetric (Figure 1b), and the proportion
of patients at each bound is low, then under the location
shift alternative hypothesis, the t-test appears to be
slightly more powerful than the MW test at detecting dif-
ferences in means.
Use of the bootstrap to estimate Type I error
The bootstrap methodology provides an ideal opportu-
nity to consider Type I errors. Resampling Algorithm 1 can
easily be adapted for this. It simply involves modification
of step 1 and not adding δ to the second simulated sample
of patients. Under the true null hypothesis of no differ-
ence in distributions, the actual Type I error rate can be
computed by determining the proportion of simulated
cases which had significance levels at or below its nominal
value. For a nominal Type I error rate of α = 0.05, we
would expect 5% (or 0.05) of the bootstrap samples to
give a (false-positive) significant result under the true null
hypothesis of no difference in distributions. The robust-
ness of each test can then be determining by comparing
the actual Type I error rates to the nominal Type I error
rates.
Statistical tests are said to be robust if the observed Type I
error rates are close to the pre-selected or nominal, Type I
error rates in the presence of violations of assumptions
[24,25]. Sullivan and D'Agostino [26] describe a test as
'robust' if the actual significance level does not exceed
10% of the nominal significance level (e.g. less than or
equal to 0.055 when the nominal significance level is
0.05). They describe a test as 'liberal' if the observed sig-
nificance exceeds the nominal level by more than 10%.
Finally, they describe a test as 'conservative' if the actual
significance level is less than the nominal level. A
'conservative' test is of less concern, as the probability of
making a Type I error is controlled.
The overall actual significance levels relative to a nominal
level of 0.05 under the null hypothesis of no treatment
differences for the GH and RP dimensions are displayed in
Table 3 for a variety of sample sizes. Both tests (t-test and
MW) are 'robust' tests of the equality of means (and dis-
tributions) for both the GH and RP outcomes.
Extensions of the use bootstrap – odds ratio shifts rather 
than simple location shift
When using the proportional odds model to estimate
sample size, Whitehead [16] and Julious et al [27] have
pointed out that there is little increase in power (and
hence saving in the number of subjects recruited) to be
gained by increasing the number of categories in a propor-
tional odds model beyond five. Although the model is
robust to mild departures from the assumption of propor-
tional odds, with increasing numbers of categories it is
less likely that the proportional odds assumption remains
true. Therefore, to illustrate this point, we shall use thePage 9 of 17
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SF-36 to show the effect of the bootstrap sample size esti-
mator when the alternative to the null hypothesis is an
odds ratio transformation rather than a simple location
shift.
Figure 5 shows the power curves for t-test and MW test for
the RP dimension of the SF-36 assuming the alternative
hypothesis is a proportional odds shift in HRQoL of OROr-
dinal = 1.50. As one would expect, the bootstrap power
curves in Figure 5 show that the MW test or the equivalent
Estimated power curves for the SF-36 General Health dimension using general population data (females aged 16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replic tionsFigure 2
Estimated power curves for the SF-36 General Health dimension using general population data (females aged 
16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replications SF-36 General Health Dimension (General 
Population Females aged 16–45); n= 487; mean = 74.8; sd = 19.6; 14.2% scoring 95 or more.Page 10 of 17
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Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/26proportional odds model is more powerful than the t-test
when the alternative hypothesis is an odds ratio shift,
although the differences in power for a given sample size
are small.
Sample sizes of over 450 patients per group are required
to have an 80% chance of detecting this 'small to moder-
ate' odds ratio (OR = 1.5) effect as statistically significant
at the 5% two-sided level. With such 'large' sample sizes
statistical theory, via Central Limit Theorem (CLT), guar-
Estimated power curves for the SF-36 Role Physical dimension using general population data (females aged 16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replicationsFigure 3
Estimated power curves for the SF-36 Role Physical dimension using general population data (females aged 
16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replications SF-36 Role Limitations Physical Dimension 
(General Population Females aged 16–45); n= 487; mean = 85.5; sd = 29.1; 75.4% scoring 100.Page 11 of 17
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mally distributed, which ensures the relatively good
performance of the t-test in detecting an OR location shift.
The robustness of the two independent samples t-test
when applied to three-, four- and five-point ordinal scaled
data has previously been demonstrated by Heeren and
D'Agostino [25] for far smaller sample sizes than this (as
small as 20 per group).
Estimated power curves for the SF-36 Energy/Vitality dimension using general population data (females aged 16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replica ionsFigure 4
Estimated power curves for the SF-36 Energy/Vitality dimension using general population data (females aged 
16–45), based on α = 0.05 (two-sided) with 10,000 bootstrap replications SF-36 Energy Dimension (General Popula-
tion Females aged 16–45); n= 487; mean = 59.3; sd = 21.1; 1% scoring 100.Page 12 of 17
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Choice of sample size method with HRQoL outcomes
It is important to make maximum use of the information
available from other related studies or extrapolation from
other unrelated studies. The more precise the information
the better we can design the trial. We would recommend
that researchers planning a study with HRQoL measures
as the primary outcome pay careful attention to any evi-
dence on the validity and frequency distribution of the
HRQoL measures and its dimensions.
The frequency distribution of HRQoL dimension scores
from previous studies should be assessed to see what
methods should be used for sample size calculations and
analysis. If the HRQoL outcome has a limited number of
discrete values (say less than seven categories e.g. RP and
RE dimensions, in the case of the SF-36, Figures 1c and 1f)
and/or the proportion of cases at the upper bound (i.e.
scoring 100) is high (e.g. PF, SF and BP dimensions in our
general population sample example dataset, Figures
1a,1e,1f), then we would recommend using Method 3 to
estimate the required sample size (Figure 6) [16]. In this
case, the alternative hypothesis of a location shift model
is questionable and the proportional odds model will
provide a suitable alternative with such bounded discrete
outcomes.
If the HRQoL outcome has a larger number of discrete val-
ues (greater than or equal to seven categories say), most of
which are occupied and the proportion of cases at the
upper or bounds (i.e. scoring 0 or 100, in the case of the
SF-36) is low (e.g. VT, GH and MH dimensions in our gen-
eral population sample example dataset, Figures 1b,1g
and 1h), then the simple location shift model is a useful
working hypothesis. We would therefore recommend
using Methods (1) or (2) to estimate the required sample
size (Figure 6).
Computer simulation has suggested that if the distribu-
tions of the HRQoL dimensions are reasonably symmetric
(Figure 1b), and the proportion of patients at each bound
is low, then under the location shift alternative hypothe-
sis, the t-test appears to be slightly more powerful than the
MW test at detecting differences in means (Figure 4).
Therefore, if the distribution of the HRQoL outcomes is
symmetric or expected to be reasonably symmetric and
the proportion of patients at the upper or lower bounds is
low then Method 1 could be used for sample size calcula-
tions and analysis (Figure 6). The use of parametric meth-
ods for analysis (i.e. t-test) also enables the relatively easy
estimation of confidence intervals, which is regarded as
good statistical practice [1].
If the distribution of the HRQoL outcome is expected to
be skewed then the MW test appears to be more powerful
at detecting a location shift (difference in means) than the
t-test (Figures 2 and 3). Therefore, in these circumstances,
the MW test is preferable to the t-test and Method 2 could
be used for sample size calculations and analysis. How-
ever, using Method 2 for sample size estimation requires
the effect size to be defined in terms of Pr(Y > X), which is
difficult to quantify and interpret. Pragmatically we would
recommend Method 1 as the effect size ∆Normal is rather
easier to quantify and interpret than the effect size pNoether
required for sample size estimation using Method 2 (Fig-
ure 6).
If the HRQoL data have a symmetric distribution, the
mean and median will tend to coincide so either measure
is a suitable summary measure of location. If the HRQoL
data have an asymmetric distribution, then conventional
statistical advice would suggest that the median is the pre-
ferred summary statistic [1]. However, a case when the
mean and mean difference might be preferred (even for
skewed outcome data) as a summary measure is when
Table 3: Actual significance levels for t-test and MW test relative to nominal α = 0.05: using general population data (females aged 16–
45) for the GH and RP dimensions [10]
Sample sizes GH dimension RP Dimension
t-test MW test t-test MW test
300, 300 0.0511 0.0490 0.0504 0.0495
250, 250 0.0520 0.0535 0.0497 0.0516
200, 200 0.0543 0.0484 0.0508 0.0521
150, 150 0.0514 0.0527 0.0507 0.0510
100, 100 0.0502 0.0515 0.0518 0.0534
75, 75 0.0493 0.0515 0.0535 0.0500
50, 50 0.0506 0.0522 0.0476 0.0512
25, 25 0.0490 0.0492 0.0526 0.0478
10, 10 0.0428 0.0464 0.0393 0.0456
α = 0.05 (two-sided); 10,000 bootstrap replications.Page 13 of 17
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treatment or not to its population. The mean (along with
the sample size) provides information about the total
benefit (and total cost) from treating all patients, which is
needed as the basis for health care policy decisions [28].
We cannot estimate the total benefit (or cost) from the
sample median.
Estimated power curves for the SF-36 Role Physical dimension to detect an Odds Ratio shift using general population data (females aged 16–45) based on α = 0.05 (two-sided) with 10,000 bootstr p replicationsFigur  5
Estimated power curves for the SF-36 Role Physical dimension to detect an Odds Ratio shift using general pop-
ulation data (females aged 16–45) based on α = 0.05 (two-sided) with 10,000 bootstrap replications Five category 
SF-36 Role Physical outcome (General population Females aged 16–45); n = 487, γ = (.06, .11, .17, .25, 1.0)Page 14 of 17
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ory, using the CLT, guarantees that the sample means will
be approximately Normally distributed. Thus, if the inves-
tigator is planning a large study and the sample mean is
an appropriate summary measure of the HRQoL out-
come, then pragmatically there is no need to worry about
the distribution of the HRQoL outcome and we can use
conventional methods to calculate sample sizes. Although
the Normal distribution is strictly only the limiting form
of the sampling distribution of the sample mean as the
sample size n increases to infinity, it provides a remarka-
bly good approximation to the sampling distribution
even when n is small and the distribution of the data is far
from Normal. Generally, if n is greater than 25, these
approximations will be good. However, if the underlying
distribution is symmetric, unimodal and continuous a
value of n as small as 4 can yield a very adequate approx-
imation [29]. If a reliable pilot or historical dataset of
HRQoL data is readily available (to estimate the shape of
the distribution) then bootstrap simulation (Method 4)
will provide a more accurate and reliable sample size esti-
mate than Methods 1 to 3 (Figure 6) [30].
We had a reliable historical data set of over 400 subjects
so we had a large sample to estimate the distributions
(cdfs) Fx and Fy under the null and alternative hypotheses
using Method 4. Lesaffre et al [31] show that bootstrap
can give fairly unbiased estimates of power, though for
small pilot samples with large variability. In the absence
of a reliable pilot set, bootstrapping is not appropriate
and we will need to use conventional methods of sample
size estimation or simulation models [32]. Fortunately,
with the increasing use of HRQoL outcomes in research,
historical datasets are becoming more readily available.
White and Thompson [33] suggest the estimation of 
(and hence ) should be derived from a pilot dataset,
and that the use of baseline data or related data sets
(which we have used) is somewhat less satisfactory. They
suggest a third possibility for estimating  is to use fol-
low-up data viewed in a blinded manner, although only
when the blinding can demonstrably be preserved.
Strictly speaking, our results and conclusions only apply
to the SF-36 outcome measure. Further empirical work is
required to see whether or not these results hold true for
other HRQoL outcomes, populations and interventions.
Choice of sample size estimation flow diagramFigur  6
Choice of sample size estimation flow diagram
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other HRQoL outcomes, such as the NHP and QLQ-C30,
i.e. multi-dimensional, ordinal or discrete response cate-
gories with upper and lower bounds, and skewed distribu-
tions; therefore, we see no theoretical reason why these
results and conclusions with the SF-36 may not be appro-
priate for other HRQoL measures.
Throughout this paper, we only considered the situation
where a single dimension of HRQoL is used at a single
endpoint. We have assumed a rather simple form of the
alternative hypothesis that the new treatment/interven-
tion would improve HRQoL compared to the control/
standard therapy. This form of hypothesis (superiority vs.
equivalence) may be more complicated than actually pre-
sented. However, the assumption of a simple form of the
alternative hypothesis that new treatment/intervention
would improve HRQoL compared to the control/standard
therapy, is not unrealistic for most superiority trials and is
frequently used for other clinical outcomes.
We have based the calculations above on the assumption
that there is a single identifiable endpoint, or HRQoL out-
come, upon which treatment comparisons are based (in
our case the GH dimension of the SF-36). Sometimes
there is more than one endpoint of interest; HRQoL out-
comes are multi-dimensional (e.g. the SF-36 has eight
dimensions including GH). If one of these dimensions is
regarded as more important than the others, it can be
named as the primary endpoint and the sample size esti-
mates calculated accordingly. The remainder should be
consigned to exploratory analyses or descriptions only
[3]. Fairclough gives a more comprehensive discussion of
multiple endpoints and suggests several methods for ana-
lysing HRQoL outcomes [34].
More work is required on what is a clinically meaningful
effect sizes for the SF-36 and other HRQoL outcomes.
There is an extensive literature on the important issue of
clinically meaningful change and the minimum impor-
tant difference (MID) for HRQoL outcomes. As the sub-
ject of this paper is the use of computer intensive methods
such as the bootstrap we have played down the issue of
the MID. Again for brevity and practical purposes of sam-
ple size estimation this paper has assumed the MID for the
SF-36 outcome is around five points for each dimension.
This is an important issue in sample size estimation. The
interested reader is referred to a series of papers from the
Clinical Significance Consensus Meeting Group for more
detailed discussion [35].
Conclusion
Finally, we would stress the importance of a sample size
calculation (with all its attendant assumptions), and that
any such estimate is better than no sample size calculation
at all, particularly in a trial protocol [36]. The mere fact of
calculation of a sample size means that a number of fun-
damental issues have been thought about: what is the
main outcome variable, what is a clinically important
effect, and how is it measured? The investigator is also
likely to have specified the method and frequency of data
analysis. Thus, protocols that are explicit about sample
size are easier to evaluate in terms of scientific quality and
the likelihood of achieving objectives.
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